TSPO and early-onset autosomal dominant Alzheimer disease: The other research have highlighted the potential of neuroactive steroids as therapeutic option for neurodegenerative diseases, such as Alzheimer’s disease (AD), due to translocator protein (TSPO) and 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) have been studied in relation to their mitochondrial dysfunction and neurosteroidgenesis (85).